CN102548988B - 阿齐沙坦有机胺盐及其制备方法和用途 - Google Patents

阿齐沙坦有机胺盐及其制备方法和用途 Download PDF

Info

Publication number
CN102548988B
CN102548988B CN2010800449716A CN201080044971A CN102548988B CN 102548988 B CN102548988 B CN 102548988B CN 2010800449716 A CN2010800449716 A CN 2010800449716A CN 201080044971 A CN201080044971 A CN 201080044971A CN 102548988 B CN102548988 B CN 102548988B
Authority
CN
China
Prior art keywords
azilsartan
organic amine
amine salt
preparation
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2010800449716A
Other languages
English (en)
Chinese (zh)
Other versions
CN102548988A (zh
Inventor
吕爱锋
杨宝海
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority to CN2010800449716A priority Critical patent/CN102548988B/zh
Publication of CN102548988A publication Critical patent/CN102548988A/zh
Application granted granted Critical
Publication of CN102548988B publication Critical patent/CN102548988B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2010800449716A 2009-11-30 2010-11-29 阿齐沙坦有机胺盐及其制备方法和用途 Expired - Fee Related CN102548988B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2010800449716A CN102548988B (zh) 2009-11-30 2010-11-29 阿齐沙坦有机胺盐及其制备方法和用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN200910246554.9 2009-11-30
CN200910246554 2009-11-30
CN2010800449716A CN102548988B (zh) 2009-11-30 2010-11-29 阿齐沙坦有机胺盐及其制备方法和用途
PCT/CN2010/079222 WO2011063764A1 (zh) 2009-11-30 2010-11-29 阿齐沙坦有机胺盐及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN102548988A CN102548988A (zh) 2012-07-04
CN102548988B true CN102548988B (zh) 2013-10-23

Family

ID=44065877

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800449716A Expired - Fee Related CN102548988B (zh) 2009-11-30 2010-11-29 阿齐沙坦有机胺盐及其制备方法和用途

Country Status (11)

Country Link
US (1) US20120238606A1 (enExample)
EP (1) EP2508522A4 (enExample)
JP (1) JP2013512199A (enExample)
CN (1) CN102548988B (enExample)
AU (1) AU2010324249B2 (enExample)
BR (1) BR112012012484A2 (enExample)
CA (1) CA2782224A1 (enExample)
MX (1) MX2012005776A (enExample)
RU (1) RU2554947C2 (enExample)
WO (1) WO2011063764A1 (enExample)
ZA (1) ZA201202683B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105037341A (zh) * 2014-04-04 2015-11-11 江苏豪森药业股份有限公司 阿齐沙坦醇铵晶型及其制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2666773B1 (en) * 2011-01-20 2017-07-26 Jiangsu Hansoh Pharmaceutical Co., Ltd. Organic amine salts of azilsartan, preparation method and use thereof
JP2014530805A (ja) 2011-09-30 2014-11-20 スンシネ ルアケ プハルマ カンパニー リミテッド アジルサルタンの結晶形並びにその製造及び使用
JP2017036215A (ja) * 2013-12-27 2017-02-16 トーアエイヨー株式会社 アンジオテンシンｉｉ受容体拮抗物質の塩
CN105503848A (zh) * 2014-10-13 2016-04-20 江苏豪森药业集团有限公司 阿齐沙坦有机胺盐复合物及其制备方法和用途
CZ2014702A3 (cs) 2014-10-15 2016-04-27 Zentiva, K.S. Způsob přípravy vysoce čistého azilsartanu
KR102220011B1 (ko) * 2020-05-15 2021-02-25 대봉엘에스 주식회사 친환경 용매를 이용한 아질사탄의 제조방법 및 이에 관한 핵심 중간체 화합물
KR102862852B1 (ko) * 2022-09-19 2025-09-22 대봉엘에스 주식회사 안지오텐신 ⅱ 길항제로서의 아질사르탄 디시클로헥실아민 및 이를 유효성분으로 하는 심혈관질환 치료 또는 예방용 약학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1067890A (zh) * 1991-06-27 1993-01-13 武田药品工业株式会社 杂环化合物，其制备及应用
CN101035524A (zh) * 2004-10-07 2007-09-12 武田药品工业株式会社 预防或治疗代谢综合征的药剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA924666B (en) * 1991-06-27 1993-12-24 Takeda Chemical Industries Ltd Heterocyclic compounds, their production and use
EP1389114A2 (en) * 2001-03-08 2004-02-18 Merck & Co., Inc. Antihypertensive agent and cholesterol absorption inhibitor combination therapy
WO2003047573A1 (en) * 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
JP4484427B2 (ja) * 2001-12-03 2010-06-16 武田薬品工業株式会社 インスリン抵抗性改善剤
US20070270477A1 (en) * 2004-10-07 2007-11-22 Takeda Pharmaceutical Company Limited Agent for Prophylaxis or Treatment of Metabolic Syndrome
JP2008524186A (ja) * 2004-12-17 2008-07-10 アストラゼネカ・アクチエボラーグ ケモカイン受容体活性の調節のためのチアゾロピラミジン化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1067890A (zh) * 1991-06-27 1993-01-13 武田药品工业株式会社 杂环化合物，其制备及应用
CN101035524A (zh) * 2004-10-07 2007-09-12 武田药品工业株式会社 预防或治疗代谢综合征的药剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105037341A (zh) * 2014-04-04 2015-11-11 江苏豪森药业股份有限公司 阿齐沙坦醇铵晶型及其制备方法

Also Published As

Publication number Publication date
AU2010324249A1 (en) 2012-05-03
AU2010324249B2 (en) 2014-08-28
HK1164310A1 (en) 2012-09-21
CA2782224A1 (en) 2011-06-03
CN102548988A (zh) 2012-07-04
MX2012005776A (es) 2012-06-13
US20120238606A1 (en) 2012-09-20
RU2012124332A (ru) 2014-01-10
JP2013512199A (ja) 2013-04-11
ZA201202683B (en) 2013-08-28
WO2011063764A1 (zh) 2011-06-03
EP2508522A4 (en) 2013-05-08
RU2554947C2 (ru) 2015-07-10
EP2508522A1 (en) 2012-10-10
BR112012012484A2 (pt) 2016-04-12

Similar Documents

Publication Publication Date Title
CN102548988B (zh) 阿齐沙坦有机胺盐及其制备方法和用途
DK2046732T5 (en) Improving the bioavailability of active substances with amidine function in drugs.
WO2010053120A1 (ja) カルバメート化合物又はその塩
CN103717219B (zh) 左心室舒张功能改善剂
TWI519531B (zh) 阿齊沙坦有機胺鹽及其製備方法和用途
US11008311B2 (en) Potassium salt of benzimidazole compound and preparation method therefor, composition and application thereof
KR20210122898A (ko) 항미생물 화합물, 조성물, 및 그의 용도
CN105777664A (zh) 2-（2-苄亚肼基）噻唑-5-羧酸酯及其制备方法与医药用途
CN101434595A (zh) 抗真菌剂-硫色满酮缩氨基(硫)脲系列物
TW448176B (en) Phenylcyclohexylcarboxamides, their preparation and pharmaceutical composition containing the same
US20170362237A1 (en) Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications
US20140228319A1 (en) Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications
HK1164310B (en) Azilsartan organic amine salts, preparation method and use thereof
TW201113525A (en) Methods for diagnosing diabetes and determining effectiveness of treatments
KR20160080116A (ko) 약학 물질로 사용되는 아미노산 유도체
US20190117624A1 (en) Therapeutic agent for inflammatory bowel diseases
CN101511816B (zh) 具有改善的生物利用度的氨基异喹啉凝血酶抑制剂
US20190263825A1 (en) Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications
HK40004308A (en) Inflammatory intestinal disease therapeutic agent
WO2017176777A1 (en) Bta-c585 for the treatment and/or prevention of conditions related to or associated with hyperuricemia or hyperuricosuria and other conditions
HK1169826B (en) Azilsartan organic amine salts, process of preparing them and the use thereof
KR20160027967A (ko) 전구약물을 생성하기 위한 아미드옥심 카르복실산 에스테르류 및 엔-하이드록시구아니딘 카르복실산 에스테르류의 용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1164310

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160310

Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu

Patentee after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd.

Address before: Tenth Industrial Zone, Lianyungang Development Zone, Jiangsu

Patentee before: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131023

CF01 Termination of patent right due to non-payment of annual fee